SAB Biotherapeutics, Inc.
SABSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 24, 2026 | Barclays | Eliana Merle | $13.00(+236%) | $3.87 | TheFly |
| May 20, 2026 | Jefferies | $11.00(+210%) | $3.55 | TheFly | |
| May 12, 2026 | H.C. Wainwright | Emily Bodnar | $10.00(+174%) | $3.65 | TheFly |
| Jan 7, 2026 | UBS | Michael Yee | $7.00(+93%) | $3.62 | StreetInsider |
| Sep 17, 2025 | Leerink Partners | $7.00(+171%) | $2.58 | TheFly | |
| Jun 7, 2024 | Loop Capital Markets | Kumaraguru Raja | $8.00(+182%) | $2.84 | StreetInsider |
| Apr 2, 2024 | H.C. Wainwright | Edward White | $6.00(+40%) | $4.29 | StreetInsider |
| Aug 11, 2022 | Chardan Capital | $3.00(+168%) | $1.12 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Jun 17, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 15, 2026 |
| Leerink Partners | maintain | Outperform | Jun 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2026 |
| Rodman & Renshaw | maintain | Buy | May 11, 2026 |
| Chardan Capital | maintain | Buy | Mar 11, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 10, 2026 |
| Chardan Capital | maintain | Buy | Dec 18, 2025 |
| Chardan Capital | maintain | Buy | Nov 17, 2025 |
| Chardan Capital | maintain | Buy | Sep 19, 2025 |
| Chardan Capital | maintain | Buy | Aug 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 22, 2025 |
| Chardan Capital | maintain | Buy | May 15, 2025 |
| Chardan Capital | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 29, 2025 |
| Chardan Capital | maintain | Buy | Jan 29, 2025 |
| Chardan Capital | maintain | Buy | Nov 7, 2024 |
| Oppenheimer | maintain | Outperform | Sep 12, 2024 |
| Chardan Capital | maintain | Buy | Sep 9, 2024 |
| Chardan Capital | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 21, 2024 |
| Chardan Capital | maintain | Buy | May 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2024 |
Earnings History
Next report: Mar 8, 2027 · EPS est. $-0.28| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.24 | $-0.27 | — | $125.0K |
| Aug 6, 2026 | $-0.28 | $-0.28 | — | $125.0K |
| May 12, 2026 | $-0.35 | $-0.20 | — | $125.0K |
| Mar 9, 2026 | $-0.46 | $-0.16 | — | $100.0K |
| Nov 14, 2025 | $-0.21 | $-0.59 | — | $100.0K |
| Aug 7, 2025 | $-1.09 | $-0.82 | — | $83.3K |
| May 9, 2025 | $-0.56 | $-1.00 | — | $125.0K |
| Mar 28, 2025 | $-1.23 | $-1.16 | $100.0K | $120.0K |
News
SAB Biotherapeutics NASDAQ: SABS reaffirmed its timeline for completing enrollment in its pivotal Type 1 diabetes study by the end of 2026, as the company reported a wider research spending bill and a third-quarter net loss.
SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript
Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET to discuss the results and provide business updates.
Executives from Healios and SAB Biotherapeutics NASDAQ: SABS outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for commercial manufacturing.
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference: Date: October 20, 2026Time: 11:15 - 11:30 a.m. ETFormat: Fireside Chat Presenter: Samuel J.
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes
MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) being held October 9-11, 2026 in Philadelphia, PA. Presentations will include encore Phase 1 data for SAB-142, a potentially disease-modifying…
Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 28 - October 2, 2026 in Milan, Italy. Presented data will highlight SAB BIO's lead program, SAB-142, a pot…
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in upcoming investor conferences in September:
AWM Investment Company Inc. purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ: SABS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 375,000 shares of the company's stock, valued at approximately $1,462,000. AWM Investment Company Inc. owned 0.41% of SAB